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        Intrathymic development of T lymphocytes bear-
ing          antigen receptor (TCR        ) is one of 
the best-defi  ned ontogenetic systems in verte-
brates (  1  ). The earliest T cells express neither 
CD4 nor CD8 and are known as double-neg-
ative (DN) cells. DN cells pass through four 
successive stages (DN1  –  4), as defi  ned by dif-
ferential expression of CD25 and CD44. Cells 
at the DN3 stage recombine the TCR     gene 
to express a pre-TCR complex that propels 
DN3 cells into the DN4 stage. DN4 cells ac-
tivate CD8 transcription to become immature 
single-positive (ISP) cells that subsequently de-
repress   CD4   to become CD4  +  CD8  +   double-
positive (DP) cells (  2  ). DP cells displaying proper 
TCR         extinguish either   CD4   or   CD8   ex-
pression and mature into CD8 or CD4 SP 
cells, respectively, before their export to the 
periphery (  3  ). 
  The execution of transcriptional programs 
during development relies on precise temporal- 
and spatial-specifi  c regulation of gene expres-
sion, which in turn requires the modulation of 
chromatin structure of target genes. An impor-
tant class of enzymes capable of manipulating 
chromatin structure is the   “  chromatin-remod-
eling complexes,  ”   the multisubunit molecular 
motors that use energy derived from ATP hy-
drolysis to physically disrupt histone –  DNA con-
tacts (  4  ). The best-known chromatin remodeler 
in mammals is the Brg-associated factor (BAF) 
complex related to the yeast Swi –  Snf complex ( 5  ). 
The BAF complex contains     10 subunits, in-
cluding the ATPase Brg or its homologue Brm. 
In addition to Brg/Brm, several other subunits 
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  We have developed a general strategy for creating littermates bearing either a tissue-
specifi  c point mutation or deletion in any target gene, and used the method to dissect the 
roles of Brg, the ATPase subunit of the chromatin-remodeling Brg-associated factor (BAF) 
complex, in early thymocyte development. We found that a point mutation that inactivates 
the Brg ATPase recapitulates multiple defects previously described for Brg deletion (Chi, 
T.H., M. Wan, P.P. Lee, K. Akashi, D. Metzger, P. Chambon, C.B. Wilson, and G.R. Crabtree. 
2003.   Immunity  . 19:169  –  182). However, the point mutant helps reveal unexpected roles 
of Brg in CD25 repression and CD4 activation. Surprisingly, CD4 activation occurs indepen-
dently of the Brg ATPase and is perhaps mediated by physical interactions between Brg and 
the   CD4   locus. Our study thus suggests that the BAF complex harbors novel activities that 
can be necessary and even suffi  cient for stimulating transcription from an endogenous 
chromatin template in the absence of Brg-dependent remodeling of that template. We 
conclude that conditional point mutants, rarely used in mammalian genetics, can help 
uncover important gene functions undetectable or overlooked in deletion mutants. 
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tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
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mutation also reveals a role of Brg in CD25 regulation not 
detected in the Brg deletion mutant. 
    RESULTS   
  Generation of littermates bearing a thymocyte-specifi  c 
Brg point mutation or Brg deletion 
  We fi  rst generated a bifunctional Brg allele (Brg  O  ) that is nor-
mally a null allele but can be conditionally turned into the 
point mutant allele expressing the Brg (K785R) protein. Spe-
cifi  cally, we introduced K/R point mutation into the exon 
that encodes part of the ATP-binding site in the Brg ATPase 
domain (  Fig. 1 A  ).   At the same time, we placed, downstream 
of the mutant exon, a removable promoter-trapping cassette 
consisting of a splice acceptor (SA) and the neomycin resis-
tance gene (Neo). Upon splicing, the promoter-trapping cas-
sette captures the mutant exon, leading to the production of 
a fusion protein between the N terminus (aa 1  –  813) of Brg 
and Neo. This fusion protein is unstable and, therefore, does 
not act as a dominant negative to interfere with the function 
of the WT Brg protein (see   Fig. 1 H  ), but it can be converted 
into the full-length Brg (K/R) protein upon Cre-mediated 
excision of the gene-trapping cassette and subsequent resto-
ration of correct splicing between the mutant exon and the 
downstream exon (  Fig. 1 A  ). We then bred mice bearing the 
Brg  O   allele, the   “  traditional  ”   fl  oxed Brg (  Brg    F  ) allele (  8, 19  ), 
and the transgene expressing Cre in thymocytes from the LCK-
proximal promoter (LCK-Cre;   Fig. 1 B  ) (  20  ). In these mice, 
nonthymocytes express Brg (1  –  813)  –  Neo fusion and WT 
Brg from the   Brg    O   and   Brg    F   alleles, respectively, whereas in 
thymocytes, the fusion is converted into the Brg (K/R) point 
mutant and WT Brg is eliminated. These mice can be generated 
within the same litters as   Brg    F/F  ; LCK-Cre mice by crossing 
  Brg    F/F  ; LCK-Cre with   Brg    F/O  , thus allowing direct compari-
son of the phenotypes caused by Brg point mutation versus 
Brg deletion (  Fig. 1 B  ). 
  The targeting vector is depicted in   Fig. 1 C  . The fl  oxed 
promoter-trapping cassette contains the promoterless Neo  –
  internal ribosome entry site (IRES)  –  GFP sequence down-
stream of an adenoviral SA. This cassette is fl  anked by   Brg   
genomic sequences, the left arm being a 1.8-kb genomic 
fragment containing the exon (E2) bearing K/R point muta-
tion, whereas the right arm is a 4.6-kb fragment containing 
another exon (E3). The vector was electroporated into em-
bryonic stem (ES) cells, and a total of 72 colonies emerged 
after G418 selection, 22 of which were analyzed. Expect-
edly, most of the clones express RNA in which E2 is spliced 
to Neo, as detected by RT-PCR using primers b and c rec-
ognizing E2 and Neo, respectively (  Fig. 1 D  , top). To deter-
mine whether the   Brg   locus has been targeted, RT-PCR was 
performed using primers a and c, the former recognizing an 
exon (E1) not present in the targeting vector. Clones #5 and 
#14 expressed RNA that contains E1 spliced to Neo, indi-
cating that the left arm is correctly recombined into the   Brg   locus 
in these two clones (  Fig. 1 D  , bottom). To check the inte-
gration of the right arm, DNA from these two clones was sub-
jected to PCR using primers d and e, the latter recognizing 
of the BAF complex are encoded by gene families, thus leading 
to the combinatorial assembly and generation of perhaps hun-
dreds of complexes with divergent functions (  6  ). The BAF 
complex plays diverse roles in the immune system (  7  ) and is 
essential for early T cell development, because Brg deletion 
in DN2, DN3, and DN4 cells impairs their survival, prolif-
eration, and developmental transitions, and causes premature 
CD4 expression on these cells (  8, 9  ). 
  Although the BAF complex can remodel chromatin, it might 
have functions in gene regulation beyond classical ATP-de-
pendent remodeling, as suggested by the following data. Spe-
cifi  cally, the ATPase activity of Brg and, therefore, chromatin 
remodeling by the BAF complex is critically dependent on 
a lysine residue (K785) located in the nucleotide-binding 
pocket of the ATPase domain of Brg (  10, 11  ). Remarkably, 
although the ATPase-dead Brg mutant Brg (K785R) fails to 
activate the mouse mammary tumor virus promoter integrated 
into the genome of a Brg-defi  cient cell line, it effi   ciently stim-
ulates the same promoter in transient transfection assays (  12  ). 
In contrast to the stably integrated promoter that is organized 
into nucleosomes, the transiently transfected promoter is nu-
cleosome free (  13  ), which apparently circumvents the need 
for ATP-dependent remodeling, thus revealing the potential 
of the BAF complex to activate transcription independently of 
Brg ATPase activity, although the data interpretation is con-
founded by the fact that Brg (K785R) was overexpressed in 
that study. The existence of the putative novel activities of the 
BAF complex unrelated to Brg-catalyzed remodeling is con-
sistent with the fact that although the BAF complex consists of 
10 subunits, 4 subunits (including Brg) are fully suffi   cient for 
nucleosome disruption in vitro (  14  ), which suggests that the 
remaining   “  dispensable  ”   subunits may harbor the novel activi-
ties. In addition, Brg itself may also harbor such activities in 
regions outside its ATPase domain. 
  These data raise the question of whether the phenotype 
seen in Brg-deleted thymocytes specifi  cally refl  ects defects in 
chromatin remodeling. Brg is essential for the integrity of the 
BAF complex (  15  ), for tethering the BAF complex to nu-
clear matrix (  15  ), for recruiting the BAF complex to certain 
target genes via interaction with sequence-specifi  c transcrip-
tion factors (  16  ), and presumably for stable association of the 
BAF complex with chromatin via its bromodomain and a re-
gion rich in lysines and arginines (  17, 18  ). Thus, Brg deletion 
may have completely eliminated the functions of the entire 
BAF complex, suggesting that the phenotype in Brg-deleted 
cells refl  ects both ATPase-dependent and -independent roles 
of the BAF complex in gene regulation. 
  To test whether Brg has ATPase-independent activity 
and to dissect the complex phenotype seen in Brg deletion 
mutants, we generated mice bearing a thymocyte-specific 
Brg (K785R) point mutation. These mice were produced 
within the same litters as mice lacking Brg in thymocytes, al-
lowing for direct phenotypic comparison. We found that Brg 
ATPase is generally required for Brg function, but Brg does 
have an unexpected, ATPase-independent role in CD4 regu-
lation that is obscured in the Brg deletion mutant. Brg point JEM VOL. 205, November 24, 2008 
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an exon (E4) not present in the vector. An amplicon of the 
expected size (    5 kb) was obtained, indicating correct re-
combination of the right arm (  Fig. 1 E  ). To determine whether 
Cre can indeed excise out the Neo-IRES-GFP cassette from 
the targeted locus, a Cre-expressing plasmid was electro-
porated into the ES cells, and the resultant DNA was ana-
lyzed by PCR using primers f and g recognizing the 5     LoxP 
site and a   Brg   genomic sequence downstream of the 3     LoxP 
site. Excision of the fl  oxed promoter-trapping cassette would 
shorten the distance between the two primers, leading to the 
amplifi  cation of 170 bp DNA. Indeed, rearrangement was 
specifi  cally detected in the transfected ES cells (  Fig. 1 F  ). 
  Southern blotting using a Neo probe was performed, which 
confi  rmed that the gene-trapping cassette was correctly tar-
geted and that there is no secondary integration of concate-
mers, as the latter would have generated an     13-kb band, the 
size of the linearized targeting vector (  Fig. 1 G  ). 
  Western blotting using an antibody against the N termi-
nus of Brg was performed to assess the level of Brg (1  –  813)  –
  Neo fusion protein in the ES clones. This fusion is structurally 
similar to the Brg-Neo fusion expressed by the constitutive 
  Brg   null allele (  Brg         ), the latter known to be unstable and 
undetectable by Western blotting (  21  ). Indeed, the antibody 
detected full-length Brg but not the fusion protein expressed 
from the   Brg    O   allele that should migrate at 120 kD (  Fig. 1 H  ), 
suggesting that the fusion protein is unstable and thus should 
not interfere with the function of WT Brg protein, although 
the protein must be present at some level to confer resistance 
to neomycin for the selection of ES cells. Alternatively, the pro-
tein may be present at a high level but still be undetectable 
because of masking of the Brg epitope, but this seems less 
likely because the   Brg    O   allele behaves as a null allele rather than 
a dominant-negative allele (see   Fig. 2 A  ). In addition, there is 
no evidence for alternative splicing between E2 and E3 in 
  Brg    O   RNA, consistent with the fact that the mRNA bearing 
E2 spliced to E3 is twofold less abundant in   Brg    O/+   cells as 
compared with WT cells (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20080938/DC1). Collectively, 
these data indicate that the   Brg    O   allele is a true null allele be-
fore the excision of the gene-trapping cassette. 
  GFP in the Brg  O   allele was intended for marking the cells 
that have undergone Cre-mediated excision; those cells should 
lose GFP expression. As GFP has a long half-life (24 h), we 
fused GFP to the protein degradation sequence PEST to re-
duce its half-life. Unfortunately, none of the ES colonies that 
emerged after G418 selection had visible GFP expression 
(unpublished data), suggesting that the rapid degradation has 
eliminated GFP protein (see Discussion). Mice bearing the 
Brg  O   allele were then generated, and their thymocytes were 
analyzed as described below. 
  Brg  O/+   mice recapitulate the thymocyte defects 
in Brg  +/      mice 
  We fi  rst determined the thymic phenotypes in Brg  O/+   mice 
bearing the Brg  O   allele together with the WT Brg allele. De-
velopmental stages of thymocytes are usually defi  ned by a 
CD4/CD8 expression pattern, but such a defi  nition is invalid 
if the coreceptors are misregulated, as in the case of Brg dele-
tion that derepresses CD4 while impairing CD8 expression 
(  8, 22  ). We therefore used CD25/CD44, together with CD3, 
as maturation markers, as previously described (  8, 22  ). In 
brief, total thymocytes are fi  rst resolved into mature (CD3  hi  ) 
and immature (CD3      /lo  ) subsets based on CD3 expression 
(  Fig. 2 A  , column 1).   The immature thymocytes are then re-
solved into two major subsets, namely DN3 (CD25  +  CD44       ) 
and post-DN3 (CD25       CD44       ;   Fig. 2 A  , column 2) before 
each population is analyzed for CD4/CD8 expression (col-
umns 3  –  5). In WT mice, the DN3 cells are, by defi  nition, 
CD4       CD8        (  Fig. 2 A  , row A, column 3). The post-DN3 
compartment in WT mice consists of DN4 (CD4       CD8       ), 
ISP (CD4       CD8  +  ), and DP cells; the DN4 and ISP subsets are 
enriched and detectable only within the   “  post-DN3 blasts  ”   
population, the most immature cells in the post-DN3 pool 
marked by high forward scatter and a complete lack of CD3 
expression (FS  hi  CD3       ;   Fig. 2 A  , row A, column 5). 
  We have previously shown that in Brg  +/      mice, the only 
detectable phenotype is impairment in CD8 expression in early 
thymocytes, which is manifested as a triad of concurrent de-
velopmental defects within post-DN3 blasts: loss of ISP cells, 
emergence of a novel CD4  +  CD8        population, and reduction 
in CD8 expression in early DP cells (  22  ). These defects are 
recapitulated in Brg  O/+   mice (  Fig. 2 A  , row B, column 5), as 
expected from the fact that the Brg  O   allele is a null allele by 
default. In addition, as in the case of Brg  +/      mice, there is no 
other obvious thymocyte defect in Brg  O/+   mice. In particular, 
these mice contain normal numbers of cells in the DN4 com-
partment, reinforcing the notion that deleting one allele of 
Brg is not suffi   cient to derepress CD4 (  22  ). 
  Loss of DN4 cells in Brg  O/+  ; LCK-Cre  +/      mice 
  We next examined the eff  ects of Brg point mutation on T 
cell development by introducing the LCK-Cre transgene into 
Brg  O/+   mice. There is no gross defect in T cell development 
in Brg  O/+  ; Cre  +/      mice, although the total thymocyte num-
ber is mildly reduced (from     136 to     98 million;   Fig. 2 A  , 
row C, column 1), largely because of a decrease in DP cells. 
Neither is there a signifi  cant change in the cellularity of the 
peripheral CD4 and CD8 cells (unpublished data). As in Brg  O/+   
mice, CD8 expression in early thymocytes is impaired, resulting 
in the loss of ISP and emergence of CD4  +  CD8        cells, but the 
CD8 expression level on DP cells seems less aff  ected (  Fig. 2 A  , 
row C, column 5). Surprisingly, DN4 cells are completely 
missing in Brg  O/+  ; Cre  +/      mice (red circles). As DN4 cells are 
an essential intermediate in T cell development, these cells must 
be present but have somehow become phenotypically unde-
tectable (see Discussion). 
  We then analyzed the status of the Brg  O   allele in various 
cell types isolated from the Brg  O/+  ; Cre  +/      mice. The Brg  O   
allele appears to be fully converted to the Brg (K/R) allele in 
DP cells and in peripheral CD4 and CD8 cells, as indicated 
by the loss of the Brg  O   allele, whereas DN3 cells show little 
conversion (  Fig. 2 B  , top). The loss of the Brg  O   allele was 2816 CONDITIONAL BRG POINT MUTATION   | Jani et al. 
    Figure 1.         Generation of conditional Brg (K785R) point mutation.   (A) A removable promoter-trapping cassette is used to generate a bifunctional 
  Brg   allele that is normally a null allele but is converted into the point mutant allele expressing Brg(K785R) upon Cre expression. (B) Brg (K785R) is spe-
cifi  cally expressed in thymocytes in mice bearing the bifunctional allele (  Brg  O  ) in combination with the traditional fl  oxed   Brg   allele  ( Brg  F )  and  LCK-Cre 
(left). The phenotypes are then compared with that seen in traditional conditional   Brg   knockout mice (right) to reveal a potential ATPase-independent 
function of the BAF complex during T cell development. (C) Targeting strategy. Four relevant exons in the   Brg   locus are depicted, arbitrarily designated 
E1 – 4.  A  fl  oxed promoter-trapping cassette  —  consisting of an adenoviral SA, the promoterless neomycin resistant gene (Neo), IRES, a destabilized version 
of GFP, and an SV40 polyadenylation signal (pA)  —  is inserted between E2 and E3. The primers for screening ES cells (a  –  e) and for detecting Cre-mediated 
recombination (f and g) are indicated. Primers (h and i) are used for detecting the   Brg  F   allele in thymocytes (see   Fig. 2 B  ; and   Fig. 3, E and F  ). Also indi-
cated are the two exons (E3 and 4) fl  oxed in the   Brg  F   allele. The asterisks indicate Brg K/R point mutations. (D  –  H) Analysis of ES cells. The integration of 
left and right arms was screened by RT-PCR (D) and PCR (E), respectively. Cre-mediated recombination was confi  rmed by PCR (F). The targeting was 
confi  rmed with Southern blotting (G), where the genomic DNA was digested with Sca I and Not1 cutting outside and within the targeting vector, JEM VOL. 205, November 24, 2008 
ARTICLE
2817
respectively, thus releasing a 5.5-kb fragment encompassing the Neo sequence. The Brg-Neo fusion protein was analyzed by Western blotting (H). 
Primer pairs used for RT-PCR were indicated to the right of the gel images in D  –  F. The asterisk in D denotes the PCR product amplifi  ed from the mRNA 
expressed from the bifunctional allele before E2-Neo splicing, and/or from the contaminating genomic DNA sequence. Unmodifi  ed ES cells (Ctrl) are 
used as controls where indicated.     
 
accompanied by the emergence of the Brg (K/R) allele, as 
expected (unpublished data). This temporal-specifi  c conver-
sion is consistent with the progressive deletion of the Brg  F   
allele by the LCK-Cre transgene in Brg  F/+  ; Cre  +/      mice, 
where deletion is marginal in DN2 and DN3 cells but com-
plete by the DN4 stage (  8  ). 
  We conclude that the Brg  O    →  Brg (K/R) conversion is 
induced by the LCK-Cre transgene in   Brg    O/+  ; Cre  +/      mice, 
but there is no gross perturbation of thymocyte development, 
suggesting that one allele of   Brg   is largely suffi   cient to mask 
the eff  ects of Brg point mutation on thymocytes. Of note, 
this scenario is not generally true for other cell types, because 
we could not breed   Brg    O/+  ; Actin-Cre mice carrying a trans-
gene ubiquitously expressing Cre, apparently because of em-
bryonic lethality (unpublished data). 
  Phenotypic differences between   Brg    F/O  ; LCK-Cre  +/      
and   Brg    F/F  ; LCK-Cre  +/      mice 
  To fully expose the eff  ects of Brg point mutation on T cell 
development, we generated   Brg    F/O  ; LCK-Cre  +/      mice in which 
Cre not only induces   Brg    O    →    Brg   (K/R) conversion in the   Brg    O   
allele but also deletes the   Brg    F   allele that is masking the eff  ects 
of Brg point mutation.   Brg    F/F  ; LCK-Cre  +/      mice were used 
as littermate controls. 
  We have previously reported that in   Brg    F/     ; LCK-Cre  +/      
mice bearing the   Brg    F   allele together with the constitutive   Brg   
null allele,   Brg    F   is hardly deleted in DN3 but completely de-
leted in DN4 cells, and   Brg  -deleted DN4 cells rapidly die by 
apoptosis before they can further develop (  8  ). Similarly, in 
  Brg    F/O  ; Cre  +/      mice, thymocyte numbers are severely reduced 
(    13-fold) because of a loss of post-DN3 cells, and there are 
few CD4/CD8 SP cells in the thymus or periphery, whereas 
DN3 cellularity is unaff  ected (  Fig. 2 A  , row E, columns 1, 2, 
and 6; and   Fig. 2 C  , top). This indicates that Brg ATPase is 
important for thymocyte development. However, a small num-
ber of post-DN3 cells (    5 million) manage to develop in 
  Brg    F/O  ; Cre  +/      mice, whereas post-DN3 cells are virtually ab-
sent in   Brg    F/     ; LCK-Cre  +/      mice, suggesting that Brg (K/R) 
retains the residual ability to support post-DN3 production. 
In addition, the presence of two loxP sites in the   Brg    O   allele 
might impair   Brg    F   deletion via competition for the Cre re-
combinase, thus contributing to the generation of the post-
DN3 cells. Interestingly, a similar number of post-DN3 cells 
is also generated in   Brg    F/F  ; Cre  +/      mice, which presumably also 
represents a   “  leaky  ”   phenotype resulting from incomplete   Brg    F   
deletion (  Fig. 2 A  , row F, columns 1 and 2; and   Fig. 2 C  , top). 
Importantly, the post-DN3 cells in the two   Brg   mutant strains 
diff  er in two ways, and the diff  erence apparently cannot be 
ascribed to the leakiness in the phenotype in   Brg    F/F  ; Cre  +/      
mice. First, these cells aberrantly express low to interme-
diate levels of CD25 only in   Brg    F/O  ; Cre  +/      mice (  Fig. 2 A  , 
rows D  –  F, column 2). The second diff  erence lies in the com-
position of post-DN3 cells. Specifi  cally,   Brg    F/O  ; Cre  +/      mice 
harbor a conspicuous CD4  +  CD8        population that consti-
tutes, on average, 38% of the total post-DN3 pool, whereas 
this population makes up only 14% in   Brg    F/F  ; Cre  +/      mice 
(  Fig. 2 A  , rows E and F, column 4; and   Fig. 2 C  , bottom). 
On the other hand, a CD4       CD8  +   subset, analogous to ISP 
cells, is seen only in   Brg    F/F  ; Cre  +/      mice (  Fig. 2 A  , rows E and F, 
column 4; and   Fig. 2 C  , bottom). It is not clear whether 
this subset is bona fi  de ISP cells, because the majority of this 
subset has small cell size, whereas ISP cells in WT mice are 
large blasts. 
  We then isolated major thymocyte subsets and analyzed 
the status of the   Brg   alleles. As expected, in   Brg    F/O  ; Cre  +/      
mice,   Brg    O    →    Brg   (K/R) conversion and   Brg    F   deletion are 
each minimal/undetectable in DN3 cells but appear to be 
complete in CD4  +  CD8        and DP cells (  Fig. 2 B  , middle, 
lanes 2  –  4). Similarly, in   Brg    F/F  ; Cre  +/      mice,   Brg    F   deletion is 
minimal/undetectable in DN3 and virtually complete in post-
DN3 (i.e., CD4  +  CD8       , CD4       CD8  +  , and DP) cells (  Fig. 2 B  , 
bottom, lanes 2  –  5); the presence of residual amounts of the 
  Brg    F   allele in post-DN3 cells, revealed by faint PCR bands 
in lanes 3  –  5, is consistent with the aforementioned leaky 
phenotype in these mice. We conclude that Brg point muta-
tion produces similar but not identical defects as Brg deletion. 
  Phenotypic differences in Bcl-xL-rescued thymocytes 
  Although the post-DN3 cells in the two Brg mutant strains 
show phenotypic diff  erences, these cells are scarce and are 
undergoing apoptosis, thus confounding interpretations and 
hampering mechanistic studies. To circumvent these problems, 
we introduced a transgene expressing Bcl-xL under the con-
trol of the LCK-proximal promoter (  23  ). This transgene, when 
introduced into   Brg    F/     ; Cre  +/      mice, was able to rescue Brg-
deleted DN4 cells from apoptosis, leading to their accumula-
tion (  8  ). The DN4 cells do not accumulate because they 
hyperproliferate: these cells are in fact completely cell-cycle 
arrested, and most of them are atrophic. The accumulation 
instead results from a blockade in DN4  →  DP diff  erentia-
tion, based on the fact that DP cells are virtually absent even 
though DN4 cells are abundant in   Brg    F/     ; Cre  +/     ; Bcl-xL  +/+   
mice. In addition, Brg-deleted DN3 cells, which are hardly 
detectable in   Brg    F/     ; Cre  +/      mice, are also rescued from death 
and subsequently accumulate. The accumulation similarly 
results from a blockade in diff  erentiation (into DN4 cells) 
rather than hyperproliferation, because the rescued DN3 cells 
are cell-cycle arrested. Furthermore, a subset of Brg-deleted, 
Bcl-xL  –  rescued DN3 and DN4 cells undergo premature 
CD4 derepression (  8  ). 2818 CONDITIONAL BRG POINT MUTATION   | Jani et al. 
  DN2 (CD25  +  CD44  +  ) cells in   Brg        and   Brg  * mice also 
accumulate and undergo partial CD4 derepression, but the 
extent of accumulation and CD4 derepression are rather vari-
able in both strains (unpublished data), presumably because 
of ineffi   cient and variable Cre-mediated deletion at this early 
stage. We conclude that Brg point mutation recapitulates the 
defects in cell survival, proliferation, and developmental tran-
sitions seen in Brg-deleted thymocytes, but a major diff  er-
ence between the two mutants lies in the unique ability of 
Brg point mutation to deplete CD4        DN4 cells, suggest-
ing that Brg point mutation and deletion diff  erentially aff  ect 
CD4 transcription. 
  Brg deletion decreases the probability of   CD4   transcription 
in DN4 cells 
    CD4   transcription is driven by the   CD4   promoter and en-
hancer, together with a locus control region (LCR) necessary 
for suppressing the position-eff  ect variegation in certain trans-
genic models (  1, 24  ). Overall, these positive regulatory ele-
ments are constitutively active; the stage-specifi  c fl  uctuation 
in CD4 expression depends on the   CD4   silencer that over-
rides the   CD4   enhancer/promoter, because   CD4   silencer 
deletion leads to ectopic CD4 expression in DN and CD8 
cells (  25  –  27  ). The CD4       DN4 cells have been previously ob-
served in   Brg    F/     ; Cre  +/     ; Bcl-xL  +/+   mice, constituting     37% 
of the post-DN3 population, and we have postulated that the 
CD4       DN4 cells arise because Brg deletion cannot com-
pletely inactivate the   CD4   silencer, thus leading to CD4 
derepression only in a subset of DN4 cells (  8  ). Paradoxi-
cally, Brg point mutation, presumably less eff  ective in si-
lencer inactivation, is able to deplete CD4       DN4 cells, which 
prompted us to revisit the mechanism underlying the genera-
tion of CD4       DN4 cells. 
  We noticed that although     8% of cells in   Brg  * mice fall 
within the CD4       CD8        compartment, these CD4       DN4 cells 
appear to express low levels of CD4 and blend into the 
CD4  +  CD8        pool, whereas the CD4       DN4 cells in   Brg        mice 
appear to truly lack CD4 expression, and in many cases, form 
a discrete population that can be readily discerned (  Fig. 3 A  , 
column 3, red circles). This trend is upheld in post-DN3 
blasts (  Fig. 3 A  , column 4). The data suggest that Brg point 
mutation uniformly derepresses CD4 in DN4 cells and turns 
them into CD4  +  DN4 cells, whereas Brg deletion leads to 
variegated CD4 derepression, with only a subset of DN4 cells 
expressing CD4. To explore this possibility, we used histo-
grams to quantify CD4 expression in the CD8        cells in   Fig. 3 A  , 
i.e., the blue-shaded population in post-DN3 blasts and the 
corresponding cells in the total post-DN3 pool. In both post-
DN3 blasts and the total post-DN3 pool, there is only a sin-
gle, CD4  +   population in   Brg  * mice, but   Brg        mice harbor a 
second population whose CD4 expression level is, surpris-
ingly, even lower than that on DN4 cells from WT (  Brg    F/F  ) 
mice (  Fig. 4 A  , left).   WT DN4 cells are known to marginally 
express CD4; although DN4 cells are by defi  nition CD4       , 
these cells have actually begun to turn on   CD4   transcrip-
tion and express some CD4 protein on the cell surface (  28  ). 
  The phenotype of   Brg    F/F  ; Cre  +/     ; Bcl-xL  +/+   mice (here-
after called   Brg       ) is similar to that of   Brg    F/     ; Cre  +/     ; Bcl-
xL  +/+   mice, although the former contains threefold more 
thymocytes. Specifi  cally, total thymocyte cellularity is in-
creased almost 10-fold, from 9 million in   Brg    F/F  ; Cre  +/      mice 
to 83 million in   Brg        mice (  Fig. 3 A  , row C).   As in the case 
of   Brg    F/     ; Cre  +/     ; Bcl-xL  +/+   mice, this increase results largely 
from the accumulation of CD4        DN4 and CD4  +   DN4 cells 
(  8  ), i.e., the CD4       CD8        and CD4  +  CD8        populations in the 
post-DN3 pool; these cells are mostly atrophic and, thus, de-
tectable not only within post-DN3 blasts but also in the total 
post-DN3 pool (  Fig. 3 A  , row C, columns 3 and 4). DP cells 
are present in   Brg        mice, but their cellularity relative to DN4 
cells is dramatically reduced as compared with that in WT 
mice, indicating a severe defect in the DN4  →  DP transi-
tion (  Fig. 3 A  , row A vs. C, column 3). Interestingly, the 
CD4       CD8  +   subset, conspicuous in   Brg    F/F  ; Cre  +/      mice, is 
absent from   Brg        mice (  Fig. 3 A  , row C, column 3). Brg-
deleted DN3 cells are similarly rescued, and they accumulate 
and undergo partial CD4 derepression as DN4 cells (  Fig. 3 A  , 
row C, column 2), and both DN3 and DN4 cells are cell-cycle 
arrested (  Fig. 3 B  ). 
  The phenotype of the   Brg    F/O  ; Cre  +/     ; Bcl-xL  +/+   (hereaf-
ter called   Brg  *) mice is similar to that of   Brg        mice in four 
ways: total thymocyte cellularity is signifi  cantly increased (    8-
fold) as compared with   Brg    F/O  ; Cre  +/      mice, largely because 
of an increase in post-DN3 cells (  Fig. 3 A  , column 1); DP 
cellularity relative to DN4 cells is much reduced (column 3); 
DN3 cells also accumulate and partially derepress CD4 (col-
umn 2); and fi  nally, rescued cells are growth arrested (  Fig. 3 B  ). 
Thus, Brg point mutation impairs thymocyte survival, prolif-
eration, and developmental transition, as does the Brg dele-
tion. However, there are two diff  erences between the Brg 
mutant strains. First, in   Brg  * mice, as in   Brg    F/O  ; Cre  +/      mice, 
CD25 expression is aberrantly elevated in post-DN3 cells 
(  Fig. 3 A  , column 1; and   Fig. 3 C  ), whereas this aberrance is 
not seen in   Brg        mice. Second, the composition of post-
DN3 cells diff  ers: CD4       DN4 cells constitute 25% of the total 
post-DN3 pool in   Brg        but only 9% in   Brg  * mice cells, 
whereas CD4  +  DN4 cells constitute 39% in   Brg        but 52% in 
  Brg  * mice (  Fig. 3 D  ). Thus, CD4       DN4 cells are enriched in 
  Brg        but depleted in   Brg  * mice, whereas the opposite is seen 
for CD4  +  DN4 cells. The two diff  erences between the Brg 
mutant strains cannot be ascribed to potential leakiness in the 
phenotype of   Brg        mice, because the same diff  erences are 
observed when comparing   Brg  * and   Brg    F/     ; Cre  +/     ; Bcl-xL  +/+   
mice. These diff  erences seem to have emerged in   Brg    F/O  ; Cre  +/      
and   Brg    F/F  ; Cre  +/      mice (  Fig. 2  ), but the situation there is 
complicated by cell death. 
  We then determined the status of the   Brg   alleles in DN3 
and post-DN3 cells. In   Brg        mice, as in   Brg    F/     ; Cre  +/     ; Bcl-
xL  +/+   mice (  8  ),   Brg    F   is almost completely deleted and Brg 
protein is undetectable (  Fig. 3 F  ; and   Fig. 3 G  , lanes 5  –  7), 
whereas in   Brg  * thymocytes,   Brg    F   is deleted and   Brg    O   is con-
verted, concomitantly with the expression of the Brg (K/R) 
protein (  Fig. 3 E  ; and   Fig. 3 G  , lanes 3 and 4). JEM VOL. 205, November 24, 2008 
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complete lack of CD4 expression on CD4       DN4 cells there-
fore suggests that Brg deletion blocks the onset of   CD4   tran-
scription in a subset of DN4 cells, thus revealing a positive, 
Presumably, a developmentally regulated, temporal-specifi  c 
mechanism has partially inactivated the   CD4   silencer in DN4 
cells, thus triggering the onset of   CD4   transcription. The 
    Figure 2.         Effects of Brg point mutation and Brg deletion on thymocyte development.   (A) Thymocytes were resolved into various subsets based on 
CD3, CD25, and CD44 expression, and the CD4/CD8 expression profi  le of each subset was then determined. The genotypes of the mice are indicated (far 
right). Mice in rows A  –  C were analyzed at a different time than mice in rows D  –  F. The total cell number of each strain (  ±  SD) is indicated inside the FACS 
plots in column 1. Red circles mark signifi  cantly changed populations; green borders are shown to facilitate comparisons. Note that in Brg point mutants, 
CD25 expression in post-DN3 cells is elevated, and therefore the post-DN3 gates are correspondingly enlarged (row E, column 2). Percentages of cells are 
shown. Data are representative of three independent experiments. (B) PCR analysis of the   Brg  O   and   Brg  F   alleles. DNA was isolated from thymocytes pooled 
from multiple mice to avoid sampling errors. Asterisks indicate internal controls for PCR (see Materials and methods for details). (C) Quantifi  cation of cel-
lularity. (top) Comparison of the abundance of total, DN3, and post-DN3 thymocytes in the Brg mutants relative to those in WT mice, set as 100. 
(bottom) Comparison of the percentages of various components of the post-DN3 pool in the Brg mutants. Data represent the means from three mice.     2820 CONDITIONAL BRG POINT MUTATION   | Jani et al. 
ATPase-independent role of Brg in   CD4   transcription. Inter-
estingly, in contrast to DN4 cells, the CD4 expression pattern 
on DN3 cells is indistinguishable between the two Brg mu-
tants, suggesting that Brg is dispensable for   CD4   transcription 
at this stage (  Fig. 4 A  , right). 
  To confi  rm that Brg deletion prevents the onset of   CD4   
transcription in CD4       DN4 cells, we performed semiquanti-
tative RT-PCR analysis (  Fig. 4 B  , top). As expected, in WT 
(  Brg    F/F  ) mice,   CD4   mRNA is undetectable in DN3 cells but 
becomes detectable in DN4 cells, although the expression 
level is lower than DP cells (lanes 1  –  3). Importantly,   CD4   
mRNA is indeed undetectable in CD4       DN4 cells from   Brg   
     mice (lane 7). As controls, we show that   CD4   mRNA is 
present in CD4  +   DN3/4 (but not CD4       DN3) cells in   Brg        
mice (lanes 4  –  6). Quantitative RT-PCR analysis confi  rmed 
that   CD4   mRNA is detectable in WT but not mutant DN4 
cells (  Fig. 4 B  , bottom). 
  The defect in   CD4   transcription in Brg-deleted DN4 cells 
suggests that Brg is required for the functions of the   CD4   
promoter/enhancer/LCR. However, this   “  transcription de-
fect  ”   might be an artifact resulting from a failure to inactivate 
the silencer. In this scenario, the   CD4   silencer somehow re-
mains active in Brg-deleted CD4       DN4 cells, thus blocking 
CD4 expression. To exclude this possibility, we deleted the 
  CD4   silencer in   Brg        mice by crossing   Brg        mice with si-
lencer KO mice (  25  ). Silencer deletion signifi  cantly enhances 
CD4 expression in DN4 cells from WT (  Brg    F/F  ) mice, as ex-
pected, but indeed fails to rescue CD4 expression in CD4       DN4 
cells from   Brg        mice (  Fig. 4 C  , left). Of note, silencer dele-
tion induces CD4 expression on CD4       DN3 cells in   Brg        
mice (compare   Fig. 4 C  , left, with   Fig. 4 A  , right), indicating 
that the CD4       DN3 cells are generated simply because Brg de-
letion cannot completely inactivate the silencer, and confi  rm-
ing that Brg is dispensable for CD4 expression in DN3 cells. 
  Collectively, the data show that Brg uses an ATPase-in-
dependent activity to increase the probability of CD4 expres-
sion in DN4 cells; in the absence of Brg,   CD4   transcription 
in DN4 cells becomes variegated, with only a subset of DN4 
cells expressing CD4. Furthermore, this variegated expression 
pattern, once established, seems epigenetically stable, surviv-
ing in vitro culture for at least 3 d (unpublished data). 
  Brg binds the   CD4   enhancer and LCR 
  We have previously shown that Brg binds the   CD4   silencer, 
suggesting that Brg directly regulates   CD4   silencer function 
(  22  ). To explore how Brg stimulates CD4 expression, we ana-
lyzed Brg binding to the positive regulatory elements at the 
  CD4   locus. Chromatin from various cell types was immuno-
precipitated with an anti-Brg antibody and the DNA was ana-
lyzed by two sets of PCR. The fi  rst is a multiplex PCR that 
coamplifi  es sequences from the   CD4   enhancer, promoter, and 
silencer together with a fragment from the GAPDH gene, 
which serves as an internal control (  29  ). The second is a du-
plex PCR coamplifying sequences from the   CD4   LCR and 
GAPDH genes. As expected, Brg binds the   CD4   silencer in 
DN (mostly DN3) cells from Rag2      /      mice, and in DN 
(mostly DN4) cells from   Brg  * mice (  Fig. 4 D  , top, lanes 1 and 4). 
Remarkably, in these cells, Brg also binds the   CD4   enhancer 
and LCR, although binding to the   CD4   promoter is marginal 
(  Fig. 4 D  , lanes 1 and 4). Interestingly, in DP cells from WT 
mice, Brg binds all four   CD4   regulatory elements, including 
the promoter (  Fig. 4 D  , lane 2). The binding is specifi  c because 
the signals were undetectable in DN cells from   Brg        mice or 
in B cells from WT mice (  Fig. 4 D  , lanes 3, 5, and 6). These 
data suggest that Brg facilitates   CD4   transcription in DN4 cells 
by directly acting on   CD4   enhancer/LCR. 
  Effects of Brg mutations on   CD4   enhancer/LCR accessibility 
  We have begun to explore the molecular mechanism whereby 
Brg stimulates   CD4   transcription. Our genetic data indicate 
that Brg uses a novel, ATPase-independent activity to stimulate 
  CD4   transcription, which predicts that Brg-dependent remod-
eling of the   CD4   enhancer/LCR, if any, is not relevant to the 
functions of these elements. To confi  rm this, we used restric-
tion enzymes to probe the accessibility of the   CD4   regulatory 
elements. Brg mutations strongly reduce the silencer accessibil-
ity (unpublished data), as expected from the essential role of the 
Brg ATPase in   CD4   silencer function. In contrast, Brg muta-
tions do not aff  ect the LCR accessibility, suggesting that Brg-
dependent remodeling does not play any role in LCR function 
(  Fig. 4 E  , right). Although Brg mutations do moderately reduce 
  CD4   enhancer accessibility, the extent of decrease in CD4       DN4 
cells is comparable to that in CD4  +   DN4 cells, suggesting that 
the accessibility decrease cannot explain the selective loss of 
CD4 expression in CD4       DN4 cells (  Fig. 4 E  , left). These data 
are consistent with the idea that ATP-dependent remodeling is 
dispensable for Brg to stimulate   CD4   transcription. 
    DISCUSSION   
  We have developed a method whereby mice with a thymo-
cyte-specifi  c point mutation in the Brg ATPase domain are 
generated within the same litters as mice deleting Brg in thy-
mocytes. Brg point mutation recapitulates multiple defects 
produced by Brg deletion but unexpectedly alters CD25 ex-
pression and is far more eff  ective in derepressing CD4 than 
Brg deletion. Further analysis indicates that Brg not only re-
presses CD4 in DN cells but also ensures the onset of   CD4   
transcription during DN  →  DP transition; the latter eff  ect, ob-
scured in the Brg deletion mutant, is ATPase independent 
and perhaps mediated by physical interactions between Brg 
and the   CD4   locus. This is the fi  rst demonstration that the 
ATPase-dead Brg point mutant, at a physiological concentra-
tion, is able to activate an endogenous gene. Our study thus 
proves that the BAF complex indeed harbors a novel activity 
in gene regulation distinct from ATP-dependent remodeling, 
the hallmark function of the BAF complex. Furthermore, it 
reveals that this activity is suffi   cient to regulate at least one 
target gene in the absence of Brg-dependent remodeling, which 
is counterintuitive given that endogenous genes are chroma-
tinized. Our data highlight the complexity in the mechanisms 
of gene regulation in vivo, and raise the exciting possibility 
that the novel activities of the BAF complex might be widely JEM VOL. 205, November 24, 2008 
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    Figure 3.         Phenotypic analysis of Bcl-xL  –  rescued thymocytes.   (A) CD4/CD8 expression pattern of various thymocyte subsets. Cells were 
stained and analyzed as in   Fig. 2 A  . The total cell number (  ±  SD) for each strain is indicated within the plots in column 1. Red circles mark differ-
ences in CD4 expression in the indicated subset between two mutants. The blue-shaded region in column 4 indicates the CD8        cells whose CD4 
expression was analyzed in   Fig. 4 A  . In   Brg  * mice, CD25 is elevated in post-DN3 cells, and the post-DN3 gate is enlarged accordingly (row B, col-
umn 1). Percentages of cells are shown. Data are representative of three independent experiments. (B) Histograms comparing BrdU incorporation 
effi  ciencies of DN3 and 4 cells. BrdU was injected into mice and thymocytes were analyzed 15 min later. The numbers within the plots indicate the 
percentages of BrdU  +   cells. At least two mice in each group were analyzed. (C) CD25 expression in immature T cells in A was analyzed by histo-
grams. The vertical line within the plot marks the boundary between DN3 and post-DN3 cells, with the DN3 cells located to the right of the line. 
(D) Bar graph comparing the percentages of various components of the post-DN3 pool in the Brg mutants. Data represent the means from three 
mice. (E  –  G) Analysis of   Brg  O   conversion and   Brg  F   deletion at DNA (E and F) and protein (G) levels.   Brg*   and   Brg       denote   Brg  F/O ;  Cre +/    ;  Bcl-xL +/+  
and   Brg  F/F ;  Cre +/    ;  Bcl-xL +/+   mice, respectively. The PCR assays are identical to those in   Fig. 2 B  . Cell subsets were sorted from thymocytes pooled 
from multiple mice to avoid sampling errors.     2822 CONDITIONAL BRG POINT MUTATION   | Jani et al. 
eling. Collectively, our study illustrates the power of condi-
tional point mutations, rarely used in mammalian genetics, 
for dissecting and discovering gene functions. The strategy for 
involved in the regulation of BAF target genes, although by 
themselves such activities in general appear insuffi   cient for 
gene regulation without concomitant Brg-dependent remod-
    Figure 4.         Brg promotes uniform CD4 expression in DN4 cells.   (A) Surface CD4 expression levels on the CD8        cells in post-DN3 pool (left) and on DN3 cells 
(right). The data are derived from the plots in   Fig. 3 A  . The CD8        cells within the post-DN3 blast (left) are located in the blue-shaded region in   Fig. 3 A  , column 4. 
(B)   CD4   mRNA levels in various subsets of thymocytes analyzed by semiquantitative (top) and quantitative (bottom) RT-PCR in two independent experiments. The 
quantitative RT-PCR was done in triplicates, the values were averaged and normalized to that of actin mRNA, and the normalized values were plotted relative to 
those in   Brg  F/F   DP cells, with the latter set as 100. UD, undetectable. (C) Effects of   CD4   silencer deletion on CD4 expression in   Brg       mice.  CD8       cells from blastic 
and total post-DN3 cells were analyzed for CD4 expression (left), as were DN3 cells (right). Vertical lines are shown to facilitate the comparison of fl  uorescent 
intensities. Data are representative of two independent experiments. (D) Chromatin immunoprecipitation analysis of Brg binding to   CD4   regulatory elements. A 
5-million-cell equivalent of chromatin was added to each immunoprecipitation reaction using either rabbit serum (IgG) or an anti-Brg antibody (Brg), and 40% 
of precipitated DNA was analyzed by semiquantitative PCR. At least two independent sources of cells were used for chromatin preparation. Asterisks indicate an 
amplicon from the GAPDH gene. The sizes of the amplicons (bp) are indicated (left). DN, thymocytes from Rag2     /     mice, consisting mostly of DN3 cells; DP, total 
thymocytes from TCR       /     mice; DN4, thymocytes at the DN stages from Brg mutants, 90% of which were DN4 cells (see Materials and methods). (E) Restriction 
enzyme accessibility of the   CD4   enhancer and LCR. Cells were partially digested with Dde I or BseR1 (red arrows), followed by DNA isolation and complete diges-
tion with a second enzyme (Bam H1 or Alu1) that generated normalization controls. The cleaved ends were detected by ligation-mediated PCR. The cells types 
used were the same as those in D. Note that   CD4   enhancer is equally accessible in DN and DP cells (but less so in B cells), consistent with the fact that the en-
hancer is poised for activation in DN cells (reference   38  ). The restriction enzyme cleavage sites are depicted at the bottom, where the numbers refer to the nucle-
otide positions of the sites. The sizes of the PCR amplicons are indicated at the left of the gels. Data are representative of at least three independent experiments.    JEM VOL. 205, November 24, 2008 
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the use of the destabilized version of GFP. Indeed, we have in-
troduced a gene-trapping cassette expressing a regular GFP into 
the BAF57 gene encoding another subunit of the BAF com-
plex and were able to visualize GFP in the targeted ES clones 
(unpublished data). The last feature is that our strategy can gen-
erate deletion and point mutants within the same litters, allow-
ing for the direct comparison of phenotypes. A drawback of 
our strategy is that two diff  erent alleles (i.e., a fl  oxed and a bi-
functional allele) must be generated to reveal the eff  ects of the 
point mutation, as opposed to the aforementioned methods 
that only need one conditional allele. Finally, the genes being 
targeted must be haplosuffi   cient for embryogenesis. However, 
given that traditional fl  oxed alleles have already been made for 
numerous genes, many of which are haplosuffi   cient for em-
bryogenesis, our strategy should be widely useful. 
  Dual role of the BAF complex in   CD4   regulation 
  We and others previously showed that Brg deletion disrupts 
CD4 repression in DN cells (  8, 9  ). Unexpectedly, Brg point 
mutation is more eff  ective in derepressing CD4 than the Brg 
deletion, which led to the discovery of the dual roles of Brg 
in CD4 regulation, as proposed in the model in   Fig. 5  .   In 
DN1  –  3 cells, the   CD4   promoter is completely inhibited by 
the fully active silencer. In DN4 cells, the silencer is presum-
ably beginning to be inactivated by a physiological mecha-
nism not involving Brg, thus initiating   CD4   transcription 
that culminates in full-blown CD4 expression in DP cells. Brg 
is required for CD4 silencer function in DN3 and 4, and pre-
sumably also in DN1 and 2 cells. Brg also increases the prob-
ability of   CD4   transcriptional initiation in DN4 cells. Thus, 
simultaneous generation of deletion and point mutants is gen-
erally applicable to other genes. 
  Deletion versus point mutation 
  Protein functions are typically studied by deleting the gene 
encoding the protein. This approach has several limitations. A 
protein often has multiple functions. Deletion abolishes all the 
functions, which may produce complex phenotypes, thus ob-
scuring certain defects, such as the positive role of Brg in   CD4   
regulation. On the other hand, some defects may be masked 
by the redundant action of a related protein. Such a scenario 
could potentially explain why Brg point mutation (but not Brg 
deletion) enhances CD25 expression, assuming that the Brg 
homologue Brm could compensate for Brg to repress CD25. 
  These limitations in deletion analysis may be overcome by 
introducing point mutations into relevant regions of the gene, 
because point mutations are more specifi  c, and the mutant pro-
tein may act as a dominant negative to prevent the related pro-
tein from masking the phenotypes. Point mutations may help 
uncover protein functions via other mechanisms. For example, 
a point mutation at serine 276 in the p65 subunit of NF-    b, 
which prevents p65 phosphorylation but does not aff  ect its 
DNA binding, produces developmental defects distinct from 
those seen in p65 knock-out mice, thus providing unique in-
sights into the biological functions of p65 (  30  ). As in the case of 
deletion mutations, it is often desirable to introduce point mu-
tations in a tissue-specifi  c manner, but the technology for mak-
ing such point mutations has not been well established. Before 
this work, three approaches were proposed to generate such 
mutations. The fi  rst two rely on Cre-mediated excision of an 
inverted, mutated exon that turns a WT allele into the mutant 
allele (  31, 32  ). In each case, mutant LoxP sites that enable uni-
directional recombination are used. An advantage of these 
methods is that the mutation can be introduced anywhere in 
the gene. The disadvantages are that inserting the inverted exon 
may interfere with the expression of the WT gene, and that 
Cre-mediated recombination of the mutant LoxP sites may not 
be as effi   cient as WT loxP sites (  33, 34  ). So far, no publications 
describing the successful use of these methods for generating 
conditional point mutant mice have appeared. The third strat-
egy has been successfully used to introduce mutations into the 
3     end of the GABA  A  -R gene (  35  ). In this method, the 3     por-
tion of the GABA  A  -R gene that encompasses the site to be 
mutated is fl  oxed, and a mutated version of this portion is du-
plicated and placed downstream of the endogenous locus. This 
mutant segment is transcriptionally silent until unmasked by 
Cre-mediated excision of the WT segment, where the mutant 
segment replaces the WT counterpart in the targeted gene. 
Whether this method can be used to introduce mutations else-
where in the gene remains to be demonstrated. 
  Our method has several useful features. First, mutations can 
be introduced anywhere in the gene. Second, the status of the 
bi-functional allele can theoretically be monitored using the 
GFP engineered in the gene-trapping cassette, which should 
facilitate phenotypic analysis. Although we failed to detect GFP 
expression in the targeted   Brg   allele, we believe this is caused by 
    Figure 5.         A model for the roles of Brg in   CD4   regulation.   T  cells 
develop from DN to DP cells. CD4 expression (red dots), fi  rst detected in 
DN4 cells, is controlled by the silencer (S),   CD4   promoter (P), enhancer 
(E), and LCR (L). For simplicity, the silencer is depicted to be located upstream 
of, and to act on, the   CD4   promoter (top), but the exact mechanism of 
repression is unknown. Brg plays a dual role in   CD4   regulation in DN cells 
by acting on both the silencer and enhancer/LCR, using distinct biochemi-
cal activities (bottom). Brg binds these elements, but it remains to be seen 
whether this interaction is functionally relevant.     2824 CONDITIONAL BRG POINT MUTATION   | Jani et al. 
  Flow cytometry.     Flow cytometrical analysis was performed as previously de-
scribed (  8  ), except that the samples were analyzed on LSRII (BD) at Yale Uni-
versity, which necessitated minor modifi  cations in the staining schemes. In 
brief, to analyze CD4/CD8 expression in various subsets of thymocytes, cells 
were stained with anti-CD4  –  allophycocyanin (APC), anti-CD8  –  PE-Cy7, 
anti-CD25  –  FITC, anti-CD44  –  PE, and anti-CD3  –  Cy5, and the cells were an-
alyzed as described in Results. To assay cell proliferation, BrdU was injected 
intraperitoneally and mice were killed 15 min afterward, as previously described 
(  8  ). Cells were stained with anti-CD4  –  Alexa Fluor 680, anti-CD8  –  PE-Cy7, 
anti-CD25  –  APC, anti-CD44  –  PE, and anti-BrdU  –  FITC before analysis. 
  PCR, Western blotting, and RT-PCR analysis of thymocytes.     The 
  Brg    O   and   Brg    F   alleles in thymocytes were monitored by PCR using primer 
pairs b/c and h/i, respectively, as depicted in   Fig. 1 C  ; these primers can only 
recognize the parental allele and not the recombination products. For detect-
ing the   Brg    O   allele, a fragment from the   CD4   enhancer was coamplifi  ed as an 
internal control. For detecting the   Brg    F   allele in   Brg    F/F  ; Cre; (Bcl-xL) mice, a 
fragment from the   CD4   silencer was coamplifi  ed as an internal control. How-
ever, for detecting the   Brg    F   allele in   Brg    F/O  ; Cre; (Bcl-xL) mice, the h/i primer 
pair alone is suffi   cient, because the primer pair, which binds the regions in the 
  Brg   gene fl  anking the 3     LoxP site (placed downstream of E4), not only de-
tects the   Brg    F   allele but also the   Brg    O   allele before or after its conversion, with 
the latter therefore serving as an internal control because its amplifi  cation effi   -
ciency is not aff  ected by Cre-mediated conversion. Western blotting was per-
formed using an anti-Brg antibody from Millipore. For semiquantitative 
RT-PCR, total RNA was extracted using the RNAeasy kit (QIAGEN) and 
analyzed using a one-step RT-PCR master mix (Invitrogen). For quantitative 
RT-PCR, the mRNA was fi  rst reverse-transcribed into cDNA and then 
quantifi  ed using Quantitect qPCR mix (QIAGEN). DN3, DN4, and DP 
cells from the Brg mutants were directly sorted from total thymocytes. DN3 
and DN4 cells from   Brg    F/F   mice (  Fig. 4 B  ) were fi  rst enriched by depleting 
CD8  +   cells with magnetic beads, followed by their purifi  cation via cell sort-
ing. The purity of the sorted cells exceeded 90% (not depicted). 
  Chromatin immunoprecipitation.     Thymocytes at the DN stage from   Brg  * 
mice were isolated by negative selection with biotin  –  anti-CD8/CD3 anti-
bodies and streptavidin magnetic beads (BD), which removed DP and residual 
SP cells. The majority (  >  90%) of the isolated cells were DN4 cells, with the 
remaining being DN1  –  3 cells. It is not feasible to deplete the DN2 and 3 cells 
using anti-CD25 beads, because the DN4 cells in   Brg  * mice express low to 
intermediate levels of CD25 (  Fig. 3 A  ). Thymocytes at the DN stage from   Brg   
     mice were similarly isolated except that the CD4  +   and CD4        cells were 
further separated using anti-CD4 beads; these cells were also predominantly at 
the DN4 stage. B cells were magnetically purifi  ed from WT (CD1) mice, 
with purity   >  90%. DP cells were from TCR          /      mice. Chromatin was fi  xed, 
sheared, precleared, immunoprecipitated, and analyzed by PCR essentially as 
previously described (  29  ); the Brg antibody was from Millipore. 
  Restriction enzyme accessibility assay.     The restriction enzyme accessi-
bility assay was performed as previously described (  38  ). In brief, 0.2 million 
lymphocytes were digested with restriction enzymes in 10   μ  l 1  ×   NEB diges-
tion buff  er II in the presence of 0.1% NP-40, which permeabilizes the mem-
brane. After the digestion, the reaction was heated to 80  °  C for 20 min to 
inactivate the enzyme. 1   μ  l proteinase K (10   μ  g) was added and the sample 
was digested overnight at 50  °  C. The sample was then heated to 80  °  C for 20 
min, and PMSF was added to 0.1 mM to completely inactivate proteinase K. 
DNA was directly digested with 0.3   μ  l of a second enzyme for 3 h, and a 
mixture of linkers recognizing the fi  rst and second cuts was added together 
with 0.3   μ  l NEB T4 DNA ligase. The reaction was incubated at room tem-
perature for 12 h before PCR analysis using 1   μ  l of ligated DNA. The am-
plicons were detected by primer extension using radiolabeled, nested primers. 
The amplicons were resolved on sequencing gels, and the intensity of the 
short relative to the long amplicons was taken as a measure of accessibility. 
  Online supplemental material.     Fig. S1 A shows that alternative splic-
ing in the   Brg    O   allele is undetectable. Fig. S1 B shows that Brg mRNA 
Brg deletion produces confl  icting eff  ects in DN4 cells: it 
facilitates CD4 derepression by helping inactivate the   CD4   
silencer while stochastically blocking the onset of   CD4   tran-
scription, leading to a variegated CD4 expression pattern that 
seems epigenetically stable once established. CD4 repression 
by Brg requires its ATPase, whereas an ATPase-independent 
activity is used to promote   CD4   transcription. 
  How does Brg repress   CD4  ? Brg binds the   CD4   silencer, 
where it uses the ATPase to remodel the chromatin and fa-
cilitates the entry of Runx1, a transcription repressor essential 
for CD4 inhibition in DN cells, and this eff  ect might be re-
sponsible for CD4 repression (unpublished data). The mech-
anism for positive CD4 regulation is unclear. Brg binds the 
  CD4   enhancer and LCR, suggesting that the BAF complex 
acts directly on these elements, but future experiments are 
needed to prove this; it is possible that Brg binding at the 
  CD4   enhancer/LCR is functionally irrelevant (  Fig. 5  ). For 
example, Brg may act instead by stimulating the expression of 
a transcription activator required for effi   cient CD4 expres-
sion. Interestingly, Brg is dispensable for CD4 expression in 
DN3 cells, indicating that a distinct mechanism is used to en-
sure uniform CD4 expression in these cells. Brg also seems 
dispensable for CD4 expression in DP cells, because DP cells 
in Brg      mice show uniform, high level CD4 expression. 
The role of Brg in CD4 regulation in ISP cells is unknown; 
ISP cells are undetectable in Brg      mice apparently because 
they have lost CD8 expression. 
  Finally, we note that the eff  ectiveness of Brg point muta-
tion in CD4 derepression may explain the   “  loss  ”   of DN4 
cells in   Brg    O/+  ; Cre   +/      mice. Presumably, Brg (K/R) has in-
terfered with WT Brg protein, leading to premature CD4 
expression on DN4 cells, which subsequently leave the DN4 
compartment and blend into the CD4  +  CD8        pool. 
  MATERIALS AND METHODS 
  DNA construct, ES cell targeting, and mice breeding.     To make the 
construct described in   Fig. 1 B  , we fi  rst constructed a gene-trapping cassette 
consisting of the following: (a) a 120-bp fragment from pCEM MINX con-
taining the adenovirus major late transcript splicing acceptor sequence from the 
intron 1/exon 2 boundary (a gift from S. Berget, Baylor College of Medicine, 
Houston, TX) (  36, 37  ); (b) the neomycin resistant gene; (c) IRES; (d) the hr 
GFP (Stratagene) fused to the PEST sequence; and (e) the SV40 poly A se-
quence. We then fl  oxed this cassette by inserting it into pEasy Lox (a gift from 
K. Rajewsky, Harvard University, Cambridge, MA), replacing the PGK-
Neo  –  poly A  –  LoxP sequence in the original vector. Finally, we inserted PCR-
amplifi  ed   Brg   genomic sequences upstream and downstream of the loxP sites to 
create the left and right arms, respectively. The left arm contains the exon (E2 
in   Fig. 1 C  ) encoding lysine 785, and this residue was mutated to arginine. The 
cloned fragments were sequenced in their entirety and no PCR-introduced 
error was found. The construct was electroporated into 129/S  V   ES cells and 
correctly targeted ES cells identifi  ed by RT-PCR. An ES clone was injected 
into blastocysts from C57B/6 mice to generate chimeras carrying the bifunc-
tional allele. The founders were crossed with mice bearing the   Brg    F   allele, and 
the LCK-Cre and LCK  –  Bcl-xL transgenes (gifts from C. Wilson, University 
of Washington, Seattle, WA) to generate mice with various genotypes, as de-
scribed in   Fig. 2  . The   CD4   silencer knockout mice were provided by D. Litt-
man (New York University, New York, NY). All the mice were on mixed 
genetic backgrounds, and experiments were performed according to the guide-
lines from Yale University  ’  s Institutional Animal Care and Use Committee. JEM VOL. 205, November 24, 2008 
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